# DataVital AI — MVP V1 Final Acceptance Report

**Branch:** `mvp-v1-remediation`  
**BUILD_ID:** `v80-mvp-v1-remediation`  
**Production bundle:** `/assets/index-CIBZ50tb.js` · CSS `/assets/index-DNRt8v24.css`  
**Baseline:** `57f37b5` / tag `mvp-v1-baseline-57f37b5`  
**Product-owner approval:** **NOT RECORDED**

---

## 1. Executive summary

MVP V1 remediation corrects Strategy/RCM revenue lineage, Supply Chain rate/DOS/inventory integrity, ICU vs enterprise staffing scopes, Quality zero-denominator handling, enterprise cross-domain parity (15 pairs), Enterprise Assist grounding, and an ED→Beds→ICU→Finance what-if demo. Full Vitest suite: **412 passed / 55 files**. Verdict for product-owner review: **CONDITIONALLY READY — OPEN NONCRITICAL ISSUES** (visual browser matrix NOT TESTED; Domains 12–15 PO approval NOT RECORDED; synthetic data).

## 2. Actual code and deployment baseline

| Item | Value |
|---|---|
| Baseline SHA | `57f37b5` |
| Feat commit (P0–P1) | `e2e3b95` |
| Production BUILD_ID (pre) | `v79-enterprise-integration` |
| Production BUILD_ID (post) | `v80-mvp-v1-remediation` |
| Bundle | `index-CIBZ50tb.js` |

## 3. Full defect register

See `00-baseline-and-defect-register.md`. P0-001, P1-001…007 FIXED; P2-001…004 FIXED; P3-001 FIXED; P3-002 DEFERRED (visual NOT TESTED).

## 4. P0/P1/P2 fixes

| ID | Fix |
|---|---|
| P0-001 | Strategy recognized revenue = RCM NPR |
| P1-001…004 | SC rates ≤100%, DOS units, empty buckets, roll-forward |
| P1-005 | ICU vs enterprise staffing dual scopes |
| P1-006 | Command CM Rate (%) ≠ Operating Contribution SAR |
| P1-007 | Financial terminology |
| P2-001 | QS zero device-days → null density + missing flags |
| P2-002 | Enterprise Assist grounded |
| P2-003 | 15-pair enterprise matrix + test |
| P2-004 | `ent-ed-congestion` what-if |

## 5. Canonical data model

Domain-owned views (`*View.ts`) remain sources of truth. Enterprise/Executive/Command **read** only. No independent executive ledger.

## 6. RCM/Strategy revenue reconciliation

H1 FY2026 year: RCM NPR = Strategy recognized = **50,292,914 SAR**. Allocation identity preserved (`st-rcm-revenue.test.ts`).

## 7. Financial and cost integrity

Operating contribution H1 FY2026 = **16,570,525 SAR** (NPR − synthetic eligible direct). CM Rate **32.9%**. Costs synthetic / documented — not ERP. SC consumption units linked, not double-summed into ST SAR.

## 8. ICU/Strategy workforce reconciliation

H1 FY2026: ICU gap **11,154 h** = Strategy `icuStaffingGapHours`. Enterprise gap **10,127 h** (different scope). Surplus ≠ auto ICU fill.

## 9. Supply Chain percentage validity

Availability / OTD ∈ [0,1]; monthly series ∈ [0,100]. H1 FY2026 availability **94.6%**.

## 10. Inventory and Days-of-Supply verification

Usable ÷ daily forecast; null when no demand; roll-forward exact; quarantine excluded from usable.

## 11. Quality & Safety acceptance

Reported ≠ validated ≠ near-miss ≠ harm. CLABSI/CAUTI device-days; SSI procedures. CAPA closure ≠ harm reduction. SIR unavailable. H1 FY2026 validated event rate **15.9/1k**; overdue high-risk **18**; CLABSI **1.66**.

## 12. All 15 domain status matrix

| Domains | Technical | PO |
|---|---|---|
| 1–11 | Demo Available (prior) | Approved |
| 12 RCM | Demo Available | NOT RECORDED |
| 13 QS | Demo Available | NOT RECORDED |
| 14 SC | Demo Available | NOT RECORDED |
| 15 Strategy | Demo Available | NOT RECORDED |
| Enterprise | Demo Available | NOT RECORDED |

## 13. Executive Dashboard acceptance

Net Revenue = RCM; Contribution = Strategy; denial/QS/SC from owners; no invented totals; not real-time claim.

## 14. Hospital Command Center acceptance

Exceptions include dual staffing scopes; supply/quality signals match owners; disclosure present.

## 15. Vital Assist AI capability classification

See `ai-capability-evidence.md`: rule-based alerts, deterministic calc, what-if simulation (**not** validated predictive AI), human-approved actions. Enterprise department grounded.

## 16. Enterprise cross-domain investigation test

`enterprise-cross-domain.test.ts` + CSV — 15 mandatory pairs PASS for H1–H5+ALL × 2024–2026 × year (+ sampled quarters).

## 17. All 26 new What-if test results

8 QS + 8 SC + 10 ST in `what-if-test-matrix.csv` — PASS (illustrative). Plus enterprise `ent-ed-congestion` PASS.

## 18. Previously approved-domain regression

Full suite 412/412 includes emergency/beds/ipd/opd/surgery/… reconcile tests.

## 19. UI/UX audit of all routes

**80** primary screen routes. SC axis truncate improved (28-char threshold). Visual matrix: honest **NOT TESTED** (240 viewport cells).

## 20. Data Dictionary completeness

Prior domain dictionaries retained; Strategy/SC readiness updated for v80 lineage notes. Status: Partially Mapped / Demo Available.

## 21. Source-to-Target completeness

Demo Available for synthetic mappings; Production Source Verified **never** claimed.

## 22. KPI Lineage completeness

Strategy lineage documents RCM→SL→CM; Command CM Rate ownership clarified.

## 23. Data Readiness matrix

Statuses used: Demo Available | Partially Mapped | Missing | Scenario Only. No Production Source Verified for synthetic.

## 24. Complete automated test suite totals

| Metric | Value |
|---|---|
| Test files | 55 passed |
| Tests | **412 passed** |
| Failed | 0 |
| Duration | ~14 s |

## 25. Browser test evidence

Automated visual browser sweep: **NOT TESTED**. Production spot-check of refresh BUILD_ID and critical routes planned post-merge.

## 26. Deployment commit and BUILD_ID

| Field | Value |
|---|---|
| BUILD_ID | `v80-mvp-v1-remediation` |
| Bundle | `index-CIBZ50tb.js` |
| Deploy method | Selective `cp` only (see `deployment-safety.md`) |
| Anti-rsync | Documented / followed |

## 27. Screenshots of corrected issues

Not attached in-repo; numerical before/after in `01-p0-p1-fixes.md` and this report §6–11.

## 28. Remaining limitations

- Synthetic demonstration data only.
- No verified production hospital integrations.
- No validated live clinical prediction.
- No established operational ROI.
- Visual QA matrix NOT TESTED.
- Domains 12–15 and Enterprise product-owner approval NOT RECORDED.
- Disclaimer duplication reduction limited (safety text retained).

## 29. Final technical recommendation

**CONDITIONALLY READY — OPEN NONCRITICAL ISSUES** for product-owner MVP review. Blocking P0/P1 data integrity items addressed; remaining gaps are visual verification and PO sign-off.

## 30. Product-owner approval status

**NOT RECORDED.** Do not treat this technical report as product acceptance.

---

## Supporting artifacts

- `cross-domain-reconciliation.csv`
- `what-if-test-matrix.csv`
- `visual-qa-matrix.csv`
- `ai-capability-evidence.md`
- `deployment-safety.md`
- `00-baseline-and-defect-register.md`
- `01-p0-p1-fixes.md`
- `02-phases-5-13-notes.md`
